デフォルト表紙
市場調査レポート
商品コード
967418

住血吸虫症治療薬の世界市場 (2020年~2027年)

Global Schistosomiasis Drugs Market, Size, Share, Opportunities and Forecast, 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.57円
住血吸虫症治療薬の世界市場 (2020年~2027年)
出版日: 2021年04月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の住血吸虫症向け治療薬の市場は、住血吸虫症の有病率の上昇や衛生・医療施設の不足、新興国における安全な飲料水の不足といった要因に支えられて、今後も拡大傾向が続く見通しです。特にアフリカ諸国では、農作業や家事、リクリエーション活動で住血吸虫に汚染された水に接触する人々が多く、大規模な蔓延の原因となっています。米国などの発症が一般的でない国々でも、流行地との人々の往来で患者が増える可能性があります。

世界保健機関(WHO)の推定によると、2018年には約2億9080万人が住血吸虫症の予防的治療を必要とし、そのうち9720万人以上が実際に治療を受けたと報告されています。

現在、住血吸虫症治療のために複数の新規ワクチンの治験が進行中で、それらが上市されれば、市場の成長促進にもつながると期待されています。

当レポートでは、世界の住血吸虫症向け治療薬の市場について分析し、市場の基本構造および最新情勢、全体的な市場動向の見通し (今後8年間分)、寄生部位別・品種別・薬剤の種類別・流通チャネル別および地域別の詳細動向、主な市場促進・抑制要因、市場競争構造、主要企業のプロファイル・事業戦略などについて調査しております。

目次

第1章 世界の住血吸虫症治療薬市場:分析手法・範囲

第2章 世界の住血吸虫症治療薬市場:主な傾向と動静

第3章 世界の住血吸虫症治療薬市場:エグゼクティブサマリー

第4章 世界の住血吸虫症治療薬市場:市場力学

  • 市場への影響要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響力の分析

第5章 世界の住血吸虫症治療薬市場:産業分析

  • ポーターのファイブフォース分析
  • パイプライン分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 医療費償還の分析
  • アンメットニーズ

第6章 世界の住血吸虫症治療薬市場:新型コロナウイルス感染症 (COVID-19) の分析

  • COVID-19の市場への影響の分析
    • 「ビフォーコロナ」/過去の市場シナリオ
    • 「ウィズコロナ」/現在の市場シナリオ
    • 「アフターコロナ」/将来の市場シナリオ
  • Covid-19流行中の価格動向
  • 需要・供給の変動域
  • 感染拡大時の市場に対する政府の取り組み
  • メーカー各社の戦略展開状況
  • 結論

第7章 世界の住血吸虫症治療薬市場:寄生部位別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):寄生部位別
  • 市場求心力指数:寄生部位別
    • 腸管住血吸虫症
    • 尿路住血吸虫症

第8章 世界の住血吸虫症治療薬市場:品種別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):品種別
  • 市場求心力指数:品種別
    • マンソン住血吸虫 (Schistosoma mansoni)
    • 日本住血吸虫 (Schistosoma japonicum)
    • メコン住血吸虫 (Schistosoma mekongi)
    • ギニア住血吸虫 (Schistosoma guineensis)
    • ビルハルツ住血吸虫 (Schistosoma haematobium)

第9章 世界の住血吸虫症治療薬市場:薬剤の種類別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):薬剤の種類別
  • 市場求心力指数:薬剤の種類別
    • プラジカンテル (Biltricide)
    • オキサムニキン (Vansil)
    • メトリホナート
    • その他

第10章 世界の住血吸虫症治療薬市場:流通チャネル別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):流通チャネル別
  • 市場求心力指数:流通チャネル別
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • その他

第11章 世界の住血吸虫症治療薬市場:地域別

  • イントロダクション
  • 市場規模の分析と対前年成長率 (YoY):地域別
  • 市場求心力指数:地域別
  • 北米
    • イントロダクション
    • 主要な地域固有のダイナミクス
    • サイト別の市場規模分析、および前年比成長分析(%)
    • 種別の市場規模分析、および前年比成長分析(%)
    • 市場規模分析、および前年比成長分析(%)、薬剤タイプ別
    • 流通チャネル別の市場規模分析、および前年比成長分析(%)
    • 国別の市場規模分析、および前年比成長分析(%)
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第12章 世界の住血吸虫症治療薬市場:競合情勢

  • 競争シナリオ
  • 市場ポジショニング/シェア分析
  • 企業合併・買収 (M&A) の分析

第13章 世界の住血吸虫症治療薬市場:企業プロファイル

  • Bayer AG
    • 企業概要
    • 製品のポートフォリオ/概略
    • 近年の動向
    • 財務分析:概要
  • Merck & Co., Inc.
  • Avanscure Lifesciences Pvt. Ltd.
  • Shin Poong Pharma.Co., Ltd.
  • Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
  • CBC Pharma.
  • Chemos GmbH & Co. KG.
  • VHB Life Science Inc.
  • 3S Corporation Kancera AB
  • Taj Pharmaceuticals Ltd.
  • その他の企業

第14章 世界の住血吸虫症薬市場:重要考察

第15章 DataM Intelligenceについて

目次

Global Schistosomiasis Drugs Market is segmented By Site (Intestinal Schistosomiasis, Urogenital Schistosomiasis), By Species Type (Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma guineensis, Schistosoma haematobium), By Drug Type (Praziquantel (Biltricide), Oxamniquine (Vansil), Metrifonate, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Schistosomiasis Drugs Market is expected to grow at a high CAGR of 3.8% during the forecasting period (2020-2027).

Schistosomiasis, also known as Bilharzia, Blood fluke, and Katayama fever, is an acute and chronic disease caused by the parasitic worm Schistosoma genus. The disease is spread through the waterborne transmission. The schistosoma parasites are found in rivers, lakes, water parks, ponds, swimming pools, municipal water, and streams. Infection with S. haematobium, Schistosoma mansoni, and S. japonicum causes illness in humans while less commonly, S. mekongi and S. intercalatum can cause disease. However, the worms that cause schistosomiasis are not found in the United States, but more than 200 million people are infected worldwide. Infection can be spread through direct contact with the infected animal and person. In 2015, schistosomiasis transmission had been reported from 78 countries.

Schistosomiasis symptoms occur when the body reacts to the worms' eggs. Abdominal cramps, Diarrhea, blood in the stool, blood in urine, vomiting, liver enlargement, fever, kidney damage, weakness, rash, and body aches are some of the symptoms of the disease. Some other chronic symptoms include genital lesions, vaginal bleeding, and nodules in the vulva. It is recommended by healthcare professionals for repeated examination to confirm the schistosomiasis parasite in the stool and urine. Polymerase chain reaction (PCR) tests and blood tests also help to diagnose schistosomiasis. If no eggs are found in urine or feces other tests such as endoscopy, colonoscopy, echocardiograms, ultrasound, liver biopsy, and MRI, are recommended for better diagnosis. If schistosomiasis is left untreated, it may lead to complications related to the cardiopulmonary, gastrointestinal, central nervous system, spleen, liver, bacterial infections, urinary obstruction, and even death.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The global schistosomiasis drugs market growth is driven by factors such as the rising prevalence of schistosomiasis, inadequate healthcare facilities, and lack of safe drinking water in developing countries.

Increasing incidence of Schistosomiasis is driving the market growth

More than 140 million people, 90% of who live in Africa, are infected with schistosomiasis. An estimated 700 million people are at risk of infection in 76 countries where the disease is considered endemic, as their agricultural work, domestic chores, and recreational activities expose them to infested water. Globally, 200,000 deaths are attributed to schistosomiasis annually. Transmission is interrupted in some countries.

The World Health Organization (WHO) estimates show that in 2018, about 290.8 million people required preventive treatment for schistosomiasis, out of which more than 97.2 million people were reported to have been treated while in 2017, an estimated 102.3 million people were treated.

Hence, increasing incidence of schistosomiasis is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of schistosomiasis drugs.

Growing Development of novel vaccines for the treatment of schistosomiasis is expected to drive the market growth

As per the University of Nottingham research in 2017, the infiltrin protein on a parasitic egg may be responsible for this infectious disease. This discovery is expected to create opportunities for the targeted development of vaccination. Also, the College of Science at Oregon State University (OSU), discovered a new protein in Biomphalaria glabrata snail, known as Grctm6 in 2017.

In 2015, Dr. Afzal Siddiqui, a professor at the Tech Health Sciences Center, has received a patent for a vaccine to treat schistosomiasis. The vaccine showed successful results in pre-clinical trials and undergoing clinical trials for safety and efficacy evaluation. Some patent applications have also been filed in China, India, and Brazil. Dr Siddiqui aims to develop and distribute this vaccine at affordable rates for the infected people. This is expected to drive the growth of the schistosomiasis drugs market over the forecast period.

High demand for preventive chemotherapy against schistosomiasis is boosting the schistosomiasis drugs market

As per the World Health Organization (WHO) in 2017, around 92% of people require preventive chemotherapy for schistosomiasis in Africa. Around 75% of school-aged children are at risk of morbidity from schistosomiasis. Also, 78% of the economies have an epidemic outbreak of schistosomiasis, and 52% of those countries require preventive chemotherapy. In addition, according to the WHO estimates, in 2016, around 207.7 million people required preventive chemotherapy; among them, around 111.8 million were school-aged children.

Lack of hygienic environment and safe drinking water in emerging countries is expected to drive the growth of schistosomiasis market.

In May 2017, the Global Schistosomiasis Alliance organized the world's Neglected tropical diseases (NTDs) program hosted by World Health Organizations (WHO). Several organizations from different economies supported this schistosomiasis control initiative program, which includes Chinese Centers for Disease Control and Prevention (CDC), Swiss Tropical and Public Health Institute, Research for Control and Elimination (SCORE), The Ministry of Health (MoH), and The Federal Ministry of Health Ethiopia (FMHE).

However, the high cost of drugs and stringent approval process restrains the market growth. Presence of large patient pool and unmet medical needs are anticipated to provide lucrative opportunities for the market growth.

Epidemiology

In the United States, acute and chronic schistosomiasis infections are not common. However, it is estimated that around 400,000 infected persons have immigrated to the U.S., neither susceptible snail species nor chronically infected human reservoirs sufficient to infest freshwater exists. Pathogenic schistosomes can survive and replicate in human hosts for a long time. Hence, persons who have travelled or immigrated may present to EDs with active cases of acute or chronic schistosomiasis and associated end-organ complications. Most of the infected patients remain asymptomatic. Acute symptoms are more common in nonimmune travellers because of a severe immune response following exposure.

Globally (excluding the United States), schistosomiasis is a major source of mortality and morbidity. Intestinal schistosomiasis caused by S mansoni occurs in about 52 nations, including Caribbean countries (i.e., Puerto Rico, Saint Lucia, Montserrat, Antigua, Martinique, Guadeloupe, Dominican Republic), eastern Mediterranean countries, South American countries (i.e., Brazil, Venezuela, Surinam), and most countries in Africa.

Other Schistosoma species that may cause intestinal symptoms and diseases include S japonicum, S intercalatum, and S mekongi.S intercalatum is found in about ten countries within the rain forests of Central Africa. S japonicum is endemic in 4 countries in the western Pacific region (i.e., China, Indonesia, Philippines, Thailand). S mekongi infection occurs in the Mekong River area of Southeast Asia (i.e., Kampuchea, Laos, Thailand). The urinary schistosomiasis caused by S haematobium affects 54 countries in Africa and the eastern Mediterranean.

Over 207 million people in around 74 countries have active schistosomal infection.  Of this population, around 60% have disease symptoms, including organ-specific complaints and problems related to chronic anaemia and malnutrition from the infection; more than 20 million are severely ill.

However, the targeted interventions combining snail control improved water supply quality, and treatment of infected persons, especially children, have shown success in diverse endemic areas, including China, Brazil, Egypt, and some areas of sub-Saharan Africa.

As per the WHO, the global distribution of schistosomiasis has changed. It has been eradicated from Japan and Lesser Antilles islands, the transmission has been stopped in Tunisia, and the transmission is very low in Saudi Arabia, Morocco, Venezuela, and Puerto Rico.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global schistosomiasis drugs market has seen negative growth from the COVID-19  pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.

Schistosomiasis Drugs Market Segment Analysis

The schistosomiasis drugs market can be segmented based on site, species type, drug class, and distribution channel.

By Drugs type, Praziquantel (Biltricide) is expected to witness rapid growth

Praziquantel (Biltricide): Praziquantel drug is used to treat schistosomiasis and is more effective on adult worms. Praziquantel is used for the treatment of individual patients and for mass community treatment programs. The mechanism of action is complex for this drug as it induces ultrastructural changes resulting in increased permeability to calcium ions. Calcium ions accumulate in the parasite cytosol, which leads to muscle contractions and ultimate paralysis of adult worms. The tegument membrane of the worm is damaged, exposing the worm to the immune response of the patient, which leads to worm death. The recovery rate with praziquantel is more than 85%. In persons not recovered, the egg burden is markedly decreased.

Oxamniquine (Vansil): Oxamniquine is effective only against S mansoni. The cure rate with the drug is around 60-90%. Oxamniquine is no longer available in the United States. Oxamniquine drug is metabolized into an ester by schistosomes. The drug damages the tegument of male schistosome worms so that the immune system of the patient is able to kill the organisms. It stops female worms from producing eggs. Surgical alternatives can include the removal of tumours, shunt surgeries, and granuloma removal. Its mechanism of action is complex.

Parasite species and geographical distribution of schistosomiasis

Species

Geographical distribution

Intestinal schistosomiasis

Schistosoma mansoni

Africa, the Middle East, the Caribbean, Brazil, Venezuela and Suriname

Schistosoma japonicum

China, Indonesia, the Philippines

Schistosoma mekongi

Several districts of Cambodia and the Lao People's Democratic Republic

Schistosoma guineensis and related S. intercalatum

Rain forest areas of central Africa

Urogenital schistosomiasis

Schistosoma haematobium

Africa, the Middle East, Corsica (France)

Most human schistosomiasis is caused by S haematobium, S mansoni, and S japonicum. Less prevalent species, such as S mekongi and S intercalatum, may also cause systemic human disease. Less importantly, other schistosomes with avian or mammalian primary hosts can cause severe dermatitis in humans (e.g., swimmer's itch secondary to Trichobilharzia ocellata).

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Middle East & Africa is dominating the global schistosomiasis drugs market

The Middle East & Africa region accounted for the largest share for schistosomiasis drugs market, followed by South America, Asia, Europe, and North America. South Africa is the largest contributor to the schistosomiasis drugs market in Middle East & Africa. The market in South America is expanding rapidly due to an increase in the patient population, especially in Brazil. However, Europe and Asia-Pacific are estimated to grow over the forecast period. Around 120 million people are symptomatic with schistosomiasis, with 20 million having the severe clinical disease. Over 200,000 deaths per year are due to schistosomiasis in sub-Saharan Africa. Women washing clothes in infested water are at major risk. Hygiene and playing in mud and water make children vulnerable to infection. Around forty million women of childbearing age are infected. Around 10 million women in Africa have schistosomiasis during pregnancy.

In Africa and Brazil, refugee migration to urban areas are transmitting the disease to new locations. Rising population size and growing needs for power and water have led to increasing transmission. Around 5-10% of an endemic community are heavily infected, and the remainder has mild to moderate infections. The risk of infection is highest amongst those who lived near rivers or lakes. In Uganda, almost no transmission was found to have occurred at altitudes greater than 1400 m or where the annual rainfall was less than 900 mm.

In the Western Pacific Region, the intestinal schistosomiasis, caused by Schistosoma japonicum is endemic in Philippines and China and caused by Schistosoma mekongi is endemic in two provinces in Cambodia and one province in the Lao People's Democratic Republic. Intestinal schistosomiasis can cause abdominal pain, diarrhoea and blood in the stool. Elimination of the schistosomiasis in the region is targeted through community empowerment with One Health approach, composed of health promotion, preventive chemotherapy campaigns, improved water, sanitation and hygiene (WASH), treatment and management of domestic animals and livestock and focal snail control.

Competitive Landscape

Some of the major players in schistosomiasis treatment market include Chemos GmbH & Co. KG, Shin Poong Pharma.Co. Ltd., Meher Distributors Pvt. Ltd., Merck & Co., Salvensis, Bayer AG, LondonPharma Ltd, Merck & Co., Inc., 3S Corporation Kancera AB, Taj Pharmaceuticals Ltd.,  Avanscure Lifesciences Pvt. Ltd, CBC Pharma., VHB Life Science Inc., Samarth Pharma Pvt. Ltd., Taj Pharmaceuticals Ltd., and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO). These companies offer various drugs, which are being used for preventive chemotherapy. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the schistosomiasis Drugs market globally.

In March 2019, IDDO launched a new global scientific collaboration dedicated to schistosomiasis and STHs with TDR (the Special Programme for Research and Training in Tropical Diseases). This aims to expand data re-use and collaboration and accelerate better treatment and control of these diseases, which affect more than a billion people globally.

In January 2020, Merck, a leading science and technology company, has donated 1 billion tablets of praziquantel, the standard medication for the treatment of schistosomiasis, to the World Health Organization (WHO). This marks a crucial milestone on the journey to the elimination of this neglected tropical disease (NTD) which mostly affects children in poor and rural communities. Since 2007, the company's praziquantel donations enabled the treatment of 400 million school-aged children in Sub-Saharan Africa.

Bayer AG

Overview:

Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen. Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products. The Pharmaceuticals Division focuses on prescription products, especially for women's healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.

Product Portfolio:

BILTRICIDE® (praziquantel): Praziquantel is a medication used to treat a number of types of parasitic worm infections. Specifically, it is used for schistosomiasis, clonorchiasis, opisthorchiasis, tapeworm infections, cysticercosis, hydatid disease, and other fluke infections. It should not be used for worm infections of the eye. It is taken by mouth.

Why Purchase the Report?

Visualize the composition of the schistosomiasis drugs market segmentation by site, species type, drug type and distribution channel highlighting the key commercial assets and players.

Identify commercial opportunities in schistosomiasis drugs market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of schistosomiasis drugs market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global schistosomiasis drugs market report would provide an access to an approx. 69 market data table, 66 figures and 250 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Related Topic's

Generic Drugs Market

Epilepsy Drugs Market

Table of Contents

Table of Contents

Schistosomiasis Drugs Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Schistosomiasis Drugs Market - Market Definition and Overview

Schistosomiasis Drugs Market - Executive Summary

Market Snippet by Site

Market Snippet by Species Type

Market Snippet by Drug Type

Market Snippet by Distribution Channel

Market Snippet by Region

Schistosomiasis Drugs Market-Market Dynamics

Market Impacting Factors

Drivers

Rising incidence of Schistosomiasis

XX

Restraints

Stringent regulatory approvals

XX

Opportunity

Impact Analysis

Schistosomiasis Drugs Market - Industry Analysis

Porter's Five Forces Analysis

Pipeline Analysis

Supply Chain Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Schistosomiasis Drugs Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Schistosomiasis Drugs Market - By Site

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site Segment

Market Attractiveness Index, By Site Segment

Intestinal Schistosomiasis*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Urogenital schistosomiasis

Schistosomiasis Drugs Market - By Species Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type Segment

Market Attractiveness Index, By Species Type Segment

Schistosoma mansoni*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Schistosoma japonicum

Schistosoma mekongi

Schistosoma guineensis

Schistosoma haematobium

Schistosomiasis Drugs Market - By Drug Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment

Market Attractiveness Index, By Drug Type Segment

Praziquantel (Biltricide)*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Oxamniquine (Vansil)

Metrifonate

Others

Schistosomiasis Drugs Market - By Distribution Channel

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Attractiveness Index, By Distribution Channel Segment

Hospital Pharmacies*

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Retail Pharmacies

Online Pharmacies

Others

Schistosomiasis Drugs Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Schistosomiasis Drugs Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Schistosomiasis Drugs Market- Company Profiles

Bayer AG*

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

Merck & Co., Inc.

Avanscure Lifesciences Pvt. Ltd.

Shin Poong Pharma.Co., Ltd.

Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)

CBC Pharma.

Chemos GmbH & Co. KG.

VHB Life Science Inc.

3S Corporation Kancera AB

Taj Pharmaceuticals Ltd. (List Not Exhaustive)

Schistosomiasis Drugs Market - Premium Insights

Schistosomiasis Drugs Market - DataM

Appendix

About Us and Services

Contact Us